Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
- Citation:
- J Clin Oncol vol 25 (21) 3055-60
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- CA 02599, CA 03927, CA 04326, CA 11028, CA 31946, CA 31983, CA 33601, CA 35279, CA 37135, CA 41287, CA 47577, CA 47642, CA 77597, CA 77658
- Corr. Author:
- Authors:
- Antonius A Miller Daryl J Murry Kouros Owzar Donna R Hollis Lionel D Lewis Hedy L Kindler John L Marshall Miguel A Villalona-Calero Martin J Edelman Raymond J Hohl Stuart M Lichtman Mark J Ratain
- Networks:
- Study
- CALGB-60101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1
- Keywords:
- Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Erlotinib Hydrochloride, Female, Follow-Up Studies, Humans, Kidney Diseases, Kidney Function Tests, Liver Diseases, Liver Function Tests, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Neoplasms, Probability, Quinazolines, Risk Assessment, Survival Analysis, Treatment Outcome